Strontium Chloride Sr 89

Strontium chloride Sr-89 is a beta-emitting radiopharmaceutical used for palliative treatment of bone pain from osteoblastic skeletal metastases in prostate, breast, and other cancers. Strontium-89 is selectively taken up by metabolically active bone at metastatic sites as a calcium analog via active transport by osteoblasts, delivering local beta radiation to reduce pain and tumor burden. The cytotoxic beta emissions have a path length of approximately 8 mm in tissue, limiting radiation to the immediate vicinity of the metastatic lesion.

Contains a radioactive isotope that accumulates in specific tissues or organs, enabling detection and imaging of physiological processes or pathological conditions using nuclear medicine techniques.

Yes, Strontium Chloride Sr 89 is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.